Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differentially Expressed Genes in the Peripheral Blood of Patients in Cervical Cancer

ABSTRACT: We prospectively investigated gene expression profiles of cervical cancer patients undergoing concurrent chemoradiation. Upregulated genes in the circumstance of anemia were analyzed. Peripheral blood of 20 patients (bulky stage IB –IVA cervical squamous cell carcinomas) undergoing concurrent chemoradiation at four time-points was collected. Total RNA extracted by PaxGene Blood RNA System was analyzed with microarrays and MetaCoreTM functional network analyses. Fifty-three genes were significantly differentially expressed during concurrent chemoradiation. Fetal and embryonic hemoglobin genes were upregulated when patients had been severely myelosuppressed. Twenty-eight genes significantly correlated with the hemoglobin genes are involved in responses to hypoxia and oxygenation, TGF-β signaling, cell cycle suppression, G-protein signaling, and transcriptional regulation. C-Myc has the highest rank in transcriptional co-regulation. Besides, IGKV1D-13 was significantly downregulated in patients with severe hematologic toxicity. These approaches identified biological processes in peripheral blood modulated by concurrent chemoradiation and subsequent anemia. Keywords: chemoradiation, microarray, network analysis

ORGANISM(S): Homo sapiens

PROVIDER: GSE8833 | GEO | 2007/10/20

SECONDARY ACCESSION(S): PRJNA102167

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of peripheral blood lymphocytes (PBL) from four pediatric renal allograft recipients with acute rejection and concurrent anemia

Project description:Compromised renal function after renal allograft transplantation often results in anemia in the recipient. Molecular mechanisms leading to anemia during acute rejection are not fully understood; inadequate erythropoietin production and iron deficiency have been reported to be the main contributors. To increase our understanding of the molecular events underlying anemia in acute rejection, we analyzed the gene expression profiles of peripheral blood lymphocytes (PBL) from four pediatric renal allograft recipients with acute rejection and concurrent anemia, using DNA microarrays containing 9000 human cDNA clones (representing 7469 unique genes). In these anemic rejecting patients, an 'erythropoiesis cluster' of 11 down-regulated genes was identified, involved in hemoglobin transcription and synthesis, iron and folate binding and transport. Additionally, some alloimmune response genes were simultaneously down-regulated. An independent data set of 36 PBL samples, some with acute rejection and some with concurrence of acute rejection and anemia, were analyzed to support a possible association between acute rejection and anemia. In conclusion, analysis using DNA microarrays has identified a cluster of genes related to hemoglobin synthesis and/or erythropoeisis that was altered in kidneys with renal allograft rejection compared with normal kidneys. The possible relationship between alterations in the expression of this cluster, reduced renal function, the alloimmune process itself, and other influences on the renal transplant awaits further analysis.

2005-11-01 | E-SMDB-2730 | biostudies-arrayexpress

Peripheral circulating mRNA profiling in predicting the pathological response to neoadjuvant chemoradiation for esophageal squamous cell carcinoma

Project description:Analysis of peripheral circulating mRNA expression levels in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma. The hypothesis test was that chemoradiation alters the circulating mRNA expression profiles and the profiling is predictive of pathological response. Results provide information on the response of circulating mRNAs to chemoradiation and identify novel biomarkers or targets in esophageal squamous cell carcinoma. Total RNA obtained from peripheral whole blood before and after neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma. 21 patients with 42 samples were analyzed. The expression profiles from pathological complete responders were compared to non-complete responders.

2014-01-01 | E-GEOD-43519 | biostudies-arrayexpress

Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

Project description:As a number of epigenetic alterations have been described in cervical cancer which may participate in the development and progression of this tumor, and the primary treatment for locally advanced disease is concurrent chemoradiation, we wanted to evaluate the efficacy and safety of hydralazine and valproate added to radiation and cisplatin. In addition, the transcriptome changes induced by the epigenetic drugs were also evaluated. Keywords: Cervical Cancer, epigenetic therapy, valproate, hydralazine, transcriptional response, epigenetic drugs

2007-07-31 | GSE8604 | GEO

High-throughput proteomic analysis of rectal cancer for prediction of non-complete response after concurrent chemoradiation therapy

Project description:Colorectal cancer (CRC) is the third most common lethal malignancy in Korea and worldwide. Rectal cancer patients occupy about 30% of CRC patients, and the majority of rectal cancer patients had locally advanced disease at diagnosis. The standard treatment of locally advanced rectal cancer (LARC) is neoadjuvant radiation therapy with concurrent chemotherapy (CCRT) followed by total mesorectal excision (TME). This multidisciplinary team approach improved local tumor control and overall survival of rectal cancer patients. High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.

2023-03-11 | PXD023302 | Pride

Molecular profiling of anemia in acute renal allograft rejection

2006-01-06 | GSE3976 | GEO

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

Project description:We hypothesized that miRNA regulation may be invloved in hydroxyurea-mediated fetal hemoglobin induction. Microarray analysis was utilized as an initial screening tool to determine differential miRNA expression in CD71+ erythroid cells comparing cells from control individuals without sickle cell anemia to patients with sickle cell anemia prior to treatment with hydroxyurea and patients receiving the maximum tolerated dose (MTD) of hydroxurea. CD71+ cells were isolated from whole blood of control individuals (n=2), pediatric patients without hydroxyurea treatment (n=3) and pediatric patients at hydroxyurea MTD (n=3). All 8 samples were analyzed for miRNA expression.

2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress

Peripheral circulating mRNA profiling in predicting the pathological response to neoadjuvant chemoradiation for esophageal squamous cell carcinoma

2014-01-01 | GSE43519 | GEO

The exponential slope from absolute lymphocyte counts during radiochemotherapy can predict an aggressive course of cervical cancer.

Project description:We sequenced plasma exosomal RNA obtained from 24 blood samples from 12 cervical cancer patients treated with concurrent chemoradiotherapy (CCRT) followed by intracavitary brachytherapy. The patients with 2018 International Federation of Gynecology and Obstetrics [FIGO] stage IB-3C2 at diagnosis were included. The 12 cervical cancer patients had two blood samples for each patient drawn before and after CCRT. Next generation sequencing data from plasma exosome included small RNAs, long non-coding RNAs, and mRNAs, of which miRNAs and mRNAs were used for analysis. The log2 fold change values were calculated between the two samples from each patient to detect mRNAs as predictors of slope of function estimated from ALCs and survival. We selected several potential exosomal mRNAs associated with clinical results.

2023-08-13 | E-MTAB-12187 | biostudies-arrayexpress

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

2011-11-21 | GSE32035 | GEO

Enhancing Concurrent Chemoradiation Outcome Prediction for Locally Advanced Cervical Cancer Patients Through Plasma Extracellular Vesicle Proteomics Analysis

Project description:Majority of the patients with cervical cancer present with locally advanced cervical cancer (LACC), which is primarily treated using concurrent chemoradiation (CCRT) and lacks reliable predictive biomarkers. Extracellular vesicles (EVs) could potentially define the dynamic biological response to CCRT. However, the relationship between EVs and the therapeutic response to LACC is unestablished. This study aimed to determine the relationship of plasma EVs pre- and post-CCRT in 62 patients with LACC. EVs were isolated using ultracentrifugation (UC) with size exclusion chromatography or UC alone for proteomic analyses. The plasma particle concentration significantly increased post-treatment in non-responders. The viral control process was enhanced at 1 month and adaptive immune response increased at 3 months, following the standard clinical cut-off. Sparse partial least squares-discriminant analysis revealed 8, 13, and 19 proteins at diagnosis, 1 month, and 3 months, respectively, influencing the CCRT response. Among these, FIBG, TFR1, HBA, and FINC, are poor prognostic markers in the cancer genome atlas tissue gene expression database. The discriminant model demonstrated excellent specificity and negative predictive value. In conclusion, the validation of our model underscores its reliability in determining the responsiveness to CCRT, highlighting the potential clinical applicability of EVs in improving outcomes in LACC.

2024-09-30 | PXD050754 | JPOST Repository

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data